We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Rinse and accrete

8 Feb 2016 By John Foley

AstraZeneca’s chief executive says he’s done with deals, unless they are accretive to earnings right away. That could rule out some good acquisitions, and rule in some terrible ones. Judging transactions by their effect on earnings per share is common, and a most unhealthy habit.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)